



In vitro inhibitory effects of puberulic acid on the growth of *Babesia* and *Theileria* parasites

Mahmoud AbouLaila^{1,2*},
Maram Mahmoud³, Heba
Wheeb², Arizoan
Guswanto¹, Aki Ishiyama⁴,
Masato Iwatsuki⁴,
Kazuhiko Otoguro⁴,
Satoshi Ōmura⁴, Naoaki
Yokoyama¹, Ikuo
Igarashi¹, and Soad
Menshawy²

¹ Department of Disease Control, National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-Cho, Obihiro, Hokkaido 080-8555, Japan

²Department of Parasitology, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Elbehera, Egypt

³Faculty of Pharmacy, Egypt-Japan University of Science and Technology, New Borg El-Arab City 21934, Alexandria, Egypt

⁴Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.

*Corresponding author:
Dr. Mahmoud AbouLaila

E-mail: hethet2004@yahoo.com

Abstract:

Puberulic acid, a tropolone compound, has antibacterial and antimalarial activities. In this study, we investigated the *in vitro* inhibitory effects of puberulic acid on three *Babesia* species and *Theileria equi*. Puberulic acid inhibited the growth of *Babesia bovis*, *Babesia bigemina*, *Babesia caballi*, and *Theileria equi* with IC₅₀ values of 1.79 ± 0.3, 1.58 ± 0.2, 2.6 ± 0.3, and 3.83 ± 0.4 μM, respectively, starting from an initial parasitemia of 1%. At 5 M, puberulic acid completely inhibited growth in *B. caballi*, 10 μM in *B. bovis*, and 25 μM in *B. bigemina* and *T. equi* cultures. Parasite growth was inhibited in the viability test at concentrations of 5 μM for *B. bigemina* and *B. caballi*, 10 μM for *B. bovis*, and 100 μM for *T. equi*. Puberulic acid had higher IC₅₀ values than diminazene aceturate. At the concentrations used, the DMSO solvent did not influence the growth of the parasites. According to the *in vitro* results, puberulic acid may be a promising candidate for developing a new antibabesial drug. More research, including extensive *in vivo* assessment, is urgently needed.

Key words: Puberulic acid- *Babesia* parasites- *Theileria equi* - *In vitro*

INTRODUCTION

Babesia bovis and *Babesia bigemina* are the main causative agents of bovine babesiosis worldwide (Bock et al., 2008). *Theileria equi* and *Babesia caballi* are the major pathogens of equine piroplasmiasis (Onyiche et al., 2019). The disease signs include fever, hemolytic anemia, jaundice, and hemoglobinuria. These piroplasms affect animal production and trade in many areas of the world (Bock et al., 2008; Onyiche et al., 2019). Therefore, there is an urgent need to develop either an effective vaccine or a safe drug, without

side effects, to control these parasites.

Metabolic products of microorganisms are promising sources for developing new drugs for several pathogens. They had anthelmintic and insecticidal activities (Bentley, 2008). Furthermore, they had antileishmanial (Adler-Moore et al., 2002), antitrypanosomal (Nihei et al., 2002), antimalarial (Otoguro et al., 2003), and antiamebic and anti-giardial (Liu and Weller, 1996) activities. Fungi are one of these microorganisms that produce several effective compounds, such as Tropolones.

Tropolones are a type of fungal secondary

metabolite with the structural motif of an 11-membered macrocycle derived from humulene (Li and Cox, 2022). Tropolone biosynthesis in *Penicillium stipitatum* has been studied, and a gene cluster encoding the biosynthesis of the fungal tropolone stipitatic acid in *Talaromyces stipitatus*, a synonym for *P. stipitatum*, has been discovered (Bentley and Thiessen, 1963; Davison et al., 2012). Tropolone compounds, either natural or synthetic, have several activities such as antibacterial, antifungal, insecticidal, antiviral, and antitumor (Iwatsuki et al., 2011).

Puberulic acid, a tropolone compound, was first extracted from the culture broth of a *Penicillium* species (Birkinshaw and Raistrick, 1932; Iwatsuki et al., 2011). Puberulic acid was chemically synthesized (Sennari et al., 2014; Saito et al., 2021). It has antibacterial (Oxford et al., 1942) and antimalarial (Iwatsuki et al., 2011) activities. As *P. falciparum* and *Babesia* parasites share several similarities (Krause et al., 2007), the objective of this study was to determine the inhibitory effect of puberulic acid on three *Babesia* species and *Theileria equi* *in vitro*.

MATERIALS AND METHODS

1. Chemicals:

Puberulic acid was synthesized at the Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan. We prepared a stock solution of 10 mM in dimethyl sulfoxide (DMSO). Diminazene aceturate, Ganaseg from Cieba-Gigi, Japan Ltd., was used as a control drug. A stock solution in double-distilled water (DDW) was prepared as previously indicated (AbouLaila et al., 2020). The nucleic acid stain SYBR Green I (SGI) was obtained from Lonza, USA, at a concentration of 10,000x and stored at -20 °C to be thawed Just before use, also a lysis buffer was prepared earlier, as per

the protocol described by Rizk et al. (2018), which comprised Tris (130 mM; pH 7.5), Ethylenediaminetetraacetic acid (EDTA) (10 mM), saponin (0.016%; W/V), and TritonX-100 (1.6%; V/V). The buffer was stored at 4 °C until use.

2. Parasites:

The parasites used in this study were *B. bovis* (Texas strain), *B. bigemina* (Argentina strain), and USDA strains of *B. caballi* and *T. equi* (Tuvshintulga et al., 2016).

3. In vitro culture of the parasites:

We used a continuous microaerophilous stationary phase culture system to grow parasites in cow or horse red blood cells (Bork et al., 2004). For *B. bovis*, *B. bigemina*, and *T. equi*, the culture medium M199 (Sigma-Aldrich) was supplemented with 40% cow or horse serum, 60 U/ml penicillin G, 60 mg/ml streptomycin, and 0.15 g/ml amphotericin B (Sigma-Aldrich). At 13.6 mg/ml, hypoxanthine from ICN Biomedicals, Inc. (Aurora, OH, USA) was included in the *T. equi* culture as an energetic enhancer. Antibiotics, amphotericin B, and 40% horse serum for *B. caballi* were added to the RPMI 1640 medium (AbouLaila et al., 2010a).

4. Effect of puberulic acid on host erythrocytes

Erythrocytes, bovine or equine, were incubated at 37 °C with puberulic acid at 100 µM for 3 hours and then washed with phosphate-buffered saline (PBS) three times. Subsequently, the erythrocytes were used to culture *B. bovis* and *T. equi* for 3 days using the same culture media and conditions. Fresh erythrocytes were employed as controls for culturing the two parasites. The growth of both types of cultures was examined, and any differences were recorded (AbouLaila et al., 2021).

5. In vitro growth inhibition assay:

Puberulic acid *in vitro* inhibition was determined using a fluorescence-based

assay, as previously described (**Rizk et al., 2018**). We added cow and horse RBCs with 1% parasitemia to the culture at hematocrit (HCT) values of 2.5% for *B. bovis* and *B. bigemina* and 5% for *B. caballi* and *T. equi*-packed RBC inoculum. Each well had a total volume of 100 μ l. Puberulic acid concentrations of 1, 5, 10, 25, 50, and 100 μ M were used. Negative controls containing no drug and either fresh or infected RBCs with the same HCT value were included. Diminazene aceturate concentrations of 5, 25, 50, 250, 1000, and 2000 nM were used. To see if the solvent had any effect on parasite growth, DMSO control plates were prepared for *B. bovis*, *B. bigemina*, *B. caballi*, and *T. equi* using bovine and equine RBCs at the same HCT values and puberulic acid concentrations as in the drug experiment. In a humidified multi-gas water-jacketed incubator, the plates were incubated for four days without shifting media at 37 °C in an atmosphere containing 90% N₂, 5% CO₂, and 5% O₂. A x2 SGI (10,000x) nucleic acid stain was mixed with 100 μ l of lysis buffer and added directly to each dilution by light mixing (**Rizk et al., 2018**), then stored at room temperature for 6 hours in the dark. The fluorescence values at 485 nm (excitation) and 518 nm (emission) wavelengths were determined using a fluorescence plate reader (Fluoroskan Ascent, Thermo Scientific, USA). The experiments were carried out three times in triplicate. The parasitemia levels were deliberately increased after the RBC background was removed (**Rizk et al., 2018**). To obtain IC₅₀ values, the values were used to create a regression curve.

6. Viability test:

Plates were prepared similarly to the *in vitro* inhibition assay and incubated in the same media for four days. The media were left alone, and infected

erythrocytes were transferred to a new plate containing 100 μ l of culture medium alone. The percentages of infected and fresh RBCs in the total RBC concentration were 42.8 and 57.2%, respectively. Plates were incubated in the same media for five days (**AbouLaila et al., 2018**).

7. Statistical analysis:

Using a student's *t*-test ($P < 0.05$), JMP software (SAS Inc., USA) was used to detect significant values between different concentrations and the control.

RESULTS

Puberulic acid inhibited parasite growth significantly (student's *t*-test, $P < 0.05$) at 2 μ M for *B. bovis*, *B. bigemina*, and *B. caballi* and 5 μ M for *T. equi*. The IC₅₀ values for *B. bovis*, *B. bigemina*, *B. caballi*, and *T. equi* were 1.79 ± 0.3 , 1.58 ± 0.2 , 2.6 ± 0.3 , and 3.83 ± 0.4 μ M, respectively (Table 1). At 5 nM diminazene aceturate treatment, *Babesia* species were significantly inhibited (Student's *t*-test, $P < 0.05$). Diminazene aceturate IC₅₀ values for *B. bovis*, *B. bigemina*, *B. caballi*, and *B. equi* growth inhibition were 338 ± 20 , 163 ± 18 , 7.1 ± 1 , and 612 ± 45 nM, respectively. Puberulic acid is more effective for bovine *Babesia* than equine piroplasms. Diminazene aceturate is particularly lethal to *B. caballi*. Puberulic acid inhibited growth at 5 μ M for *B. caballi*, 10 μ M for *B. bovis*, and 25 μ M for *B. bigemina* and *T. equi*. Diminazene aceturate-cured parasites were fully suppressed at a concentration of 2000 nM, whereas *B. caballi* required a concentration of 50 nM to be suppressed. In the puberulic acid viability test, parasite growth was inhibited at concentrations of 5 μ M for *B. bigemina* and *B. caballi*, 10 μ M for *B. bovis*, and 100 μ M for *T. equi* (Table 2). The diminazene aceturate-cured parasites did not re-grow in the succeeding diminazene aceturate viability test at concentrations of

Table (1): IC₅₀ values of puberulic acid for *Babesia* and *Theileria* parasites

Parasite	IC ₅₀ values (µM)	
	Puberulic acid	Diminazene aceturate
<i>B. bovis</i>	1.79 ± 0.3	0.338 ± 0.020
<i>B. bigemina</i>	1.58 ± 0.2	0.163 ± 0.018
<i>B. caballi</i>	2.6 ± 0.3	0.0071 ± 0.001
<i>T. equi</i>	3.83 ± 0.4	0.612 ± 0.045
<i>P. falciparum</i> *	0.051	ND ^a
Human MRC-5 cells*	291.72	ND ^a

^a ND is not determined. *Iwatsuki et al., 2011

Table (2): Viability of *Babesia* species and *T. equi* after 5 days of puberulic acid treatment

Parasite	Concentration (µM)						
	1	2	5	10	25	50	100
<i>B. bovis</i>	+	+	+	—	—	—	—
<i>B. bigemina</i>	+	+	—	—	—	—	—
<i>B. caballi</i>	+	+	—	—	—	—	—
<i>T. equi</i>	+	+	+	+	+	+	—

(+) viable and (—) dead

25 nM for *B. caballi* and 1000 nM for *B. bovis*, *B. bigemina*, and *T. equi*. At the concentrations used, the DMSO solvent did not influence the growth of the parasites. Puberulic acid showed no effect on the host erythrocytes, and the growth of the parasites was similar to that in the control culture.

DISCUSSION

Bovine and equine piroplasmiasis are tick-transmitted blood parasites. The disease signs include fever, hemolytic anemia, jaundice, and hemoglobinuria. These piroplasms affect animal production and trade in many areas of the world. An urgent search for effective drugs is needed because of the side effects of the current drugs. Puberulic acid, a tropolone compound, is produced by the *Penicillium* species. It has antibacterial (Oxford et al., 1942)

and antimalarial (Iwatsuki et al., 2011) activities. Due to the similarity of *P. falciparum* and *Babesia* parasites, we were encouraged to examine its *in vitro* effects on the growth of the *Babesia* species and *T. equi*.

The growth of the four parasites was inhibited by the treatment at micromolar concentrations ranging from 1.79 to 3.83 µM. The solvent DMSO did not alter the growth of the parasites at the doses used. *B. bigemina* and *B. bovis* were more susceptible than *B. caballi* and *T. equi*. The IC₅₀s of puberulic acid were higher than those of diminazene aceturate reported in this study.

IC₅₀ values of puberulic acid were higher than tulathromycin (Silva et al., 2018), actinonin on *Babesia* species (AbouLaila et al., 2014), epoxomicin (AbouLaila et al., 2010a), luteolin (AbouLaila et al.,

2019a), enrofloxacin (AbouLaila et al., 2019b), quercetin (AbouLaila et al., 2019c), clofazimine for *T. equi* (Tuvshintulga et al., 2016), Coumermycin A1 (AbouLaila et al., 2021), and methylene blue (Tuvshintulga et al., 2015). While the IC₅₀s of puberulic acid were lower than thymoquinone (El-Sayed et al., 2019), resveratrol (El-Sayed et al., 2023), enoxacin (Omar et al., 2016), apigenin except for *T. equi* (AbouLaila et al., 2018), gallic acid (AbouLaila et al., 2018), trifluralin derivatives (Silva et al., 2013), (-)-Epigallocatechin-3-gallate except for *T. equi* (AbouLaila et al., 2010b; AbouLaila et al., 2011), gedunin (Azirwan et al., 2013), ciprofloxacin, thioestrepton, and clindamycin on bovine *Babesia* and *T. equi* (AbouLaila et al., 2012), cryptolepine hydrate (Batiha et al., 2020), atranorin (Beshbishy et al., 2020), clofazimine on *Babesia* species (Tuvshintulga et al., 2016) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (Guswanto et al., 2018).

IC₅₀s of puberulic acid (1.79–3.83 μM) are higher than that of the IC₅₀ of *P. falciparum* of 0.051 μM (0.01 μg/ml) (Iwatsuki et al., 2011). This may be related to differences in parasite type and culture conditions. Puberulic acid IC₅₀ values are very low compared with the IC₅₀ value of 291.7 μM (57.2 μg/ml) for human MRC-5 cells (Iwatsuki et al., 2011). Therefore, it might be safe for the treatment of piroplasmosis.

The mechanism of action of puberulic acid on *Babesia* and *Theileria* parasites is not yet known. Puberulic acid has been shown to inhibit gram-positive bacteria (Oxford et al., 1942) and

malaria (Iwatsuki et al., 2011). In general, both natural and synthetic tropolones exhibited a wide range of biological activities, including antibacterial, antifungal, insecticidal, antiviral, and antitumor properties. Furthermore, they have been found to inhibit various enzymes, such as aminoglycoside-2-O-adenyltransferase (Allen et al., 1982), metalloprotease (Morita et al., 2003), and HIV-1 reverse transcriptase-associated ribonuclease H (Budihhas et al., 2005). Also, tropolones' inhibitory mechanisms were thought to reflect their ability to form complexes with divalent cations (Bentley, 2008). There are several ribonucleases found in the *B. bovis* genome (Yamagishi et al., 2014), such as ribonuclease H (GenBank accession No.: BBOV_I000890), CAF1 family ribonuclease containing protein (GenBank accession No.: BAN65002), ribonuclease P/MRP family protein subunit (GenBank accession No.: XP_051623651), and RNase H2 complex component family protein (GenBank accession No.: XP_001611364). Furthermore, several ribonucleases are found in the *T. equi* genome (Kappmeyer et al., 2012) such as the CAF1 family ribonuclease domain-containing protein (GenBank accession No.: XP_004830989), CAF1 family ribonuclease domain-containing protein (GenBank accession No.: AFZ81323) and ribonuclease H1 large subunit (GenBank accession No.: XP_004830217 and AFZ80551). Moreover, there are some metalloproteases in the *B. bovis* genome such as Aminopeptidase I zinc metalloprotease (GenBank accession No.: BBOV_IV011550) and ATP-dependent metalloprotease (GenBank accession No.: BBOV_III005230). Also, in the *T. equi* genome such as metalloprotease/cell

division cycle (GenBank accession No.: XM_004833698); therefore, the effect of puberulic acid might be due to targeting one or more of these enzymes, but this hypothesis requires further investigation.

CONCLUSION

According to the *in vitro* results, puberulic acid may be a promising candidate for the development of a new antibabesial drug. More research, including extensive *in vivo* assessment, is urgently needed.

REFERENCES

- AbouLaila, M., AbdEl-Aziz, A.R., Menshawy, S., Yokoyama, N., Igarashi, I., Al-Wabel, M. and Omar, M. (2021): Evaluation of the inhibitory effects of coumermycin A1 on the growth of *Theileria* and *Babesia* parasites *in vitro* and *in vivo*. Pak. Vet. J. 41, 469–474.
- AbouLaila, M., El-Sayed, S.A., Omar, M.A., Al-Aboudy, M.S., Abdel Aziz, A.R., Abdel-Daim, M.M., Rizk, M.A. and Igarashi, I. (2020): Myrrh oil *in vitro* inhibitory growth on bovine and equine piroplasm parasites and *Babesia microti* of mice. Pathogens 9, 173.
- AbouLaila, M., Abd El-Aziz, A., Yokoyama, N. and Igarashi, I. (2019a): Luteolin: target validation in *Babesia bovis* by reverse transcription-polymerase chain reaction and *in vivo* inhibition of *Babesia microti*. J. Clin. Res. Med. Rep. 1, 103.
- AbouLaila, M., AbdEl-Aziz, A., Menshawy, S., Salama, A., Mady, R., Yokoyama, N. and Igarashi, I. (2019b): Evaluation of the *in vitro* and *in vivo* inhibitory effects of enrofloxacin on the growth of *Babesia* species and *Theileria equi*. Drug-Drug Abuse 1, 2–6.
- AbouLaila, M., Abdelaziz, A., Rizk, M., Mady, R., Yokoyama, N. and Igarashi, I. (2019c): Evaluation of the *in vitro* and *in vivo* inhibitory effects of quercetin on the growth of *Babesia* and *Theileria* parasites. Damanhour J. Vet. Sci. 2, 23–27.
- AbouLaila, M.R., Abdel-Aziz, A., Menshawy, S., Mady, R., Yokoyama, N., and Igarashi, I. (2018): Evaluation of the *in vitro* and *in vivo* inhibitory effects of apigenin and gallic acid on the growth of *Babesia* and *Theileria* parasites. Egypt. Vet. Med. Soc. Parasitol. J. 14, 137–150.
- AbouLaila, M., Salam, A., Zidan, S., Shihata, A., Yokoyama, N. and Igarashi, I. (2014): Evaluation of *in vitro* inhibitory effects of actinonin on *Babesia* and *Theileria equi* parasites. Minufiya Vet. J. 8, 53–160.
- Aboulaila, M., Munkhjargal, T., Sivakumar, T., Ueno, A., Nakano, Y., Yokoyama, M., Yoshinari, T., Nagano, D., Katayama, K., El-Bahy, N., Yokoyama, N. and Igarashi, I. (2012): Apicoplast-targeting antibacterials inhibit the growth of *Babesia* parasites. Antimicrob. Agents Chemother. 56, 3196–3206.
- AbouLaila, M., Terkawi, M., Yokoyama, N. and Igarashi, I. (2011): *In vitro* growth inhibitory effect of (-)-Epigallocatechin-3-gallate from green tea on the growth of equine *Babesia* parasites. J. Protozool. Res. 21, 30–35.
- Aboulaila, M., Nakamura, K., Govind, Y., Yokoyama, N. and Igarashi, I. (2010a): Evaluation of the *in vitro* growth-inhibitory effect of epoxomicin on *Babesia* parasites. Vet. Parasitol. 167, 19–27.
- Aboulaila, M., Yokoyama, N. and Igarashi, I. (2010b): Inhibitory effects of (-)-epigallocatechin-3-gallate from green tea on the growth of *Babesia* parasites. Parasitology 137, 785–791.

- Adler-Moore, J., Proffitt, R. T. (2002): AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. *J. Antimicrob. Chemother.* 49 (Suppl. S1), 21–30.
- Allen, N., Alborn Jr, W., Hobbs Jr, J. and Kirst, H. (1982): 7-Hydroxytropolone: an inhibitor of aminoglycoside-2"-O adenylyl transferase. *Antimicrob. Agents Chemother.* 22, 824-831.
- Azirwan, G., Thillaiampalam, S., Muncharee, T., Yokoyama, N. and Igarashi, I. (2013): *In vitro* inhibitory effect of gedunin on *Babesia* and *Theileria* parasites. *J. Protozool. Res.* 23, 1–6.
- Batiha, G.E.-S., Beshbishy, A.M., Alkazmi, L.M., Nadwa, E.H., Rashwan, E.K., Yokoyama, N. and Igarashi, I. (2020): *In vitro* and *in vivo* growth inhibitory activities of cryptolepine hydrate against several *Babesia* species and *Theileria equi*. *PLoS Negl. Trop. Dis.* 14, e0008489.
- Bentley, R. (2008): A fresh look at natural tropolones. *Nat. Prod. Rep.* 25, 118–138.
- Bentley, R., Thiessen, C.P. (1963): Biosynthesis of tropolones in *Penicillium stipitatum*: I. The isolation, separation, and assay of stipitonic and stipitatic acids. *J. Biol. Chem.* 238, 1880–1888.
- Beshbishy, A.M., Batiha, G.E., Alkazmi, L., Nadwa, E., Rashwan, E., Abdeen, A., Yokoyama, N. and Igarashi, I. (2020): Therapeutic Effects of Atranorin towards the Proliferation of *Babesia* and *Theileria* Parasites. *Pathogens* 9, 127.
- Birkinshaw, J.H., Raistrick, H. (1932): Studies in the biochemistry of micro-organisms: Puberulic acid C₈H₆O₆ and an acid C₈H₄O₆, new products of the metabolism of glucose by *Penicillium puberulum* Bainier and *Penicillium aurantio-virens* Biourge. With an appendix on certain dihydroxybenzenedicarboxylic acids. *Biochem. J.* 26, 441.
- Bock, R., Jackson, L., De Vos, A. and Jorgensen, W. (2008): Babesiosis of cattle. In: *Ticks: Biology, Disease and Control*. Cambridge University Press, Cambridge, UK, pp. 281-307. doi:10.1017/CBO9780511551802.014
- Bork, S., Yokoyama, N., Ikehara, Y., Kumar, S., Sugimoto, C. and Igarashi, I. (2004): Growth-inhibitory effect of heparin on *Babesia* parasites. *Antimicrob. Agents Chemother.* 48, 236–241.
- Budihas, S.R., Gorshkova, I., Gaidamakov, S., Wamiru, A., Bona, M.K., Parniak, M.A., Crouch, R.J., McMahon, J.B., Beutler, J.A. and Le Grice, S.F. (2005): Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. *Nucleic Acids Res.* 33, 1249–1256.
- Davison, J., al Fahad, A., Cai, M., Song, Z., Yehia, S.Y., Lazarus, C.M., Bailey, A.M., Simpson, T.J. and Cox, R.J. (2012): Genetic, molecular, and biochemical basis of fungal tropolone biosynthesis. *Proc. Natl. Acad. Sci.* 109, 7642–7647.
- El-Sayed, S.A., El-Alfy, E.-S., Sayed-Ahmed, M.Z., Mohanta, U.K., Alqahtani, S.S., Alam, N., Ahmad, S., Ali, M.S., Igarashi, I. and Rizk, M.A. (2023): Evaluating the inhibitory effect of resveratrol on the multiplication of several *Babesia* species and *Theileria equi* on *in vitro* cultures, and *Babesia microti* in mice. *Front. Pharmacol.* 14, 1192999.
- El-Sayed, S.A.E., Rizk, M.A., Yokoyama, N. and Igarashi, I. (2019): Evaluation of the *in vitro* and *in vivo* inhibitory effect of

- thymoquinone on piroplasm parasites. *Parasit. Vectors* 12, 37.
- Guswanto, A., Nugraha, A.B., Tuvshintulga, B., Tayebwa, D.S., Rizk, M.A., Batiha, G.E., Gantuya, S., Sivakumar, T., Yokoyama, N. and Igarashi, I. (2018): 17-DMAG inhibits the multiplication of several *Babesia* species and *Theileria equi* on *in vitro* cultures, and *Babesia microti* in mice. *Int. J. Parasitol.: Drugs Drug Resist.* 8, 104-111.
- Iwatsuki, M., Takada, S., Mori, M., Ishiyama, A., Namatame, M., Nishihara-Tsukashima, A., Nonaka, K., Masuma, R., Otaguro, K., Shiomi, K. and Ōmura, S. (2011): *In vitro* and *in vivo* antimalarial activity of puberulic acid and its new analogs, viticolins A-C, produced by *Penicillium* sp. FKI-4410. *J. Antibiot.* 64, 183–188.
- Kappmeyer, L.S., Thiagarajan, M., Herndon, D.R., Ramsay, J.D., Caler, E., Djikeng, A., Gillespie, J.J., Lau, A.O., Roalson, E.H. and Silva, J.C. (2012): Comparative genomic analysis and phylogenetic position of *Theileria equi*. *BMC Genom.* 13, 1–13.
- Krause, P.J., Daily, J., Telford, S.R., Vannier, E., Lantos, P. and Spielman, A. (2007): Shared features in the pathobiology of babesiosis and malaria. *Trends Parasitol.* 23(12), 605–610.
- Li, L., Cox, Russell J. (2022): Stereochemical and Biosynthetic Rationalisation of the Tropolone Sesquiterpenoids. *J. Fungi* 8, 929.
- Liu, L. X., Weller, P. F. (1996): Antiparasitic drugs. *New Engl. J. Med.* 334, 1178–1184.
- Morita, Y., Matsumura, E., Okabe, T., Shibata, M., Sugiura, M., Ohe, T., Tsujibo, H., Ishida, N. and Inamori, Y. (2003): Biological activity of tropolone. *Biol. Pharm. Bull.* 26, 1487–1490.
- Nihei, C., Fukai, Y. and Kita, K. (2002): *Trypanosome* alternative oxidase as a target of chemotherapy. *Biochim. Biophys. Acta* 1587, 234–239.
- Omar, M.A., Salama, A., Elsify, A., Rizk, M.A., Al-Aboody, M.S., AbouLaila, M., El-Sayed, S.A. and Igarashi, I. (2016): Evaluation of *in vitro* inhibitory effect of enoxacin on *Babesia* and *Theileria* parasites. *Exp. Parasitol.* 161, 62–67.
- Onyiche, T.E., Suganuma, K., Igarashi, I., Yokoyama, N., Xuan, X. and Thekisoe, O. (2019): A Review on Equine Piroplasmosis: Epidemiology, Vector Ecology, Risk Factors, Host Immunity, Diagnosis and Control. *Int. J. Environ. Res. Public Health.* 16(10),1736. doi: 10.3390/ijerph16101736.
- Otaguro, K., Ui, H., Ishiyama, A., Arai, N., Kobayashi, M., Takahashi, Y., Masuma, R., Shiomi, K., Yamada, H. and Ōmura, S. (2003): *In vitro* antimalarial activities of the microbial metabolites. *J. Antibiot.* 56, 322–324.
- Oxford, A. E., Raistrick, H. and Smith, G. (1942): Anti-bacterial substances from moulds. Part VI. Puberulic acid, C₈H₆O₆, and puberolonic acid, C₈H₄O₆, metabolic products of a number of species of *Penicillium*. *Chem. Ind.* 61, 485–487.
- Rizk, M.A., AbouLaila, M., El-Sayed, S.A.E.-S., Guswanto, A., Yokoyama, N. and Igarashi, I. (2018): Inhibitory effects of fluoroquinolone antibiotics on *Babesia divergens* and *Babesia microti*, blood parasites of veterinary and zoonotic importance. *Infect. Drug Resist.* 1605–1615.
- Saito, R., Sennari, G., Nakajima, A., Kimishima, A., Iwatsuki, M., Ishiyama, A., Hokari, R., Hirose, T. and Sunazuka, T. (2021): Discoveries and syntheses of

highly potent antimalarial troponoids. Chem. Pharm. Bull. 69, 564–572.

Sennari, G., Hirose, T., Iwatsuki, M., Omura, S. and Sunazuka, T. (2014): A concise total synthesis of puberulic acid, a potent antimalarial agent. Chem. Commun. 50, 8715–8718.

Silva, M.G., Domingos, A., Esteves, M.A., Cruz, M.E. and Suarez, C.E. (2013): Evaluation of the growth-inhibitory effect of trifluralin analogues on *in vitro* cultured *Babesia bovis* parasites. Int. J. Parasitol.: Drugs Drug Resist. 3, 59–68.

Silva, M.G., Villarino, N.F., Knowles, D.P. and Suarez, C.E. (2018): Assessment of Draxxin® (tulathromycin) as an inhibitor of *in vitro* growth of *Babesia bovis*, *Babesia bigemina* and *Theileria equi*. Int. J.

Parasitol.: Drugs Drug Resist. 8, 265–270.

Tuvshintulga, B., AbouLaila, M., Davaasuren, B., Ishiyama, A., Sivakumar, T., Yokoyama, N., Iwatsuki, M., Otaguro, K., Ōmura, S. and Igarashi, I. (2016): Clofazimine inhibits the growth of *Babesia* and *Theileria* parasites *in vitro* and *in vivo*. Antimicrob. Agents Chemother. 60, 2739–2746.

Tuvshintulga, B., Sivakumar, T., Salama, A., Yokoyama, N. and Igarashi, I. (2015): Evaluation of inhibitory effect of methylene blue against *Babesia* and *Theileria* parasites. J. Protozool. Res. 25, 18–28.

Yamagishi, J., Wakaguri, H., Yokoyama, N., Yamashita, R., Suzuki, Y., Xuan, X. and Igarashi, I. (2014): The *Babesia bovis* gene and promoter model: an update from full-length EST analysis. BMC Genom. 15, 1–11.

الملخص العربي

مدى تأثير حمض البيوبيرووليك على نمو طفيليات البابييزيا و الثيليريا إكواي مختبريا

محمود أبوليلة¹ ومرام محمود³ وهبه وهيب واريوان جيسوانتو¹ واكي ايشيياما⁴ وماساتو ايواتسوكي⁴ وكازوهيكو اوتوجارو⁴ وساتوشي ايمورا⁴ وناواكي يوكوياما¹ وإكيو إجراشي وسعاد منشاوي²

قسم السيطرة على الأمراض-المركز القومي لأمراض البروتوزوا جامعة أوبيهيو-اليابان¹، قسم الطفيليات كلية الطب البيطري جامعة دمنهور-مصر² و³ كلية الصيدلة- الجامعة المصرية اليابانية-مدينة برج العرب-مصر

حمض البيوبيرووليك، هو مركب تروبولون، له نشاطات مضادة للبكتيريا والمالاريا. في هذه الدراسة، قمنا بالتحقيق في التأثيرات المثبطة لحمض البيوبيرووليك على ثلاثة أنواع من البابييزيا و الثيليريا إكواي في المختبر. ثبت حمض البيوبيرووليك نمو البابييزيا بوفيز، و البابييزيا بيجيمينا، و البابييزيا كابالي، و الثيليريا إكواي بقيم IC_{50} بلغت 0.3 ± 1.79 ، 0.2 ± 1.58 ، 0.3 ± 2.6 ، و 0.4 ± 3.83 ميكرومولار على التوالي، بدءًا من طفيلية أولية بنسبة 1%. عند 5 ميكرومولار، ثبت حمض البيوبيرووليك النمو تمامًا في طفيليات البابييزيا كابالي، و 10 ميكرومولار في البابييزيا بوفيز، و 25 ميكرومولار في البابييزيا بيجيمينا و الثيليريا إكواي. تم تثبيط نمو الطفيليات في اختبار إعادة الحيوية بتركيزات 5 ميكرومولار للبابييزيا بيجيمينا و البابييزيا كابالي، و 10 ميكرومولار للبابييزيا بوفيز، و 100 ميكرومولار للثيليريا إكواي. كان لحمض البيوبيرووليك قيم IC_{50} أعلى من أسيتات الاديمنازين. في التركيزات المستخدمة، لم يؤثر المذيب دايمثيل سلفوكسيد على نمو الطفيليات. وفقًا للنتائج المختبرية، قد يكون حمض البيوبيرووليك مرشحًا واعدًا لتطوير عقار جديد مضاد للبابييزيا. هناك حاجة ملحة لمزيد من البحث، بما في ذلك تقييم واسع النطاق في الكائنات الحية.